Longitudinal trends in health-related quality of life in adults with cystic fibrosis

Chest

Volumn 144, Issue 3, 2013, Pages 981-989

  Dill, Edward J ^a   Dawson, Ree ^b   Sellers, Deborah E ^d   Robinson, Walter M ^d   Sawicki, Gregory S ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d EDUCATION DEVELOPMENT CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CYSTIC FIBROSIS; CYSTIC FIBROSIS QUESTIONNAIRE REVISED; DEMOGRAPHY; DISEASE EXACERBATION; EMOTION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH SURVEY; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; TREND STUDY; UNITED STATES;

EID: 84884326788     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1404     Document Type: Article

References (27)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report for 2009. Bethesda, MD: Cystic Fibrosis Foundation; 2010.
2. Abbott J, Hart A. Measuring and reporting quality of life outcomes in clinical trials in cystic fi brosis: a critical review. Health Qual Life Outcomes. 2005 ; 3 (1): 19.
3. Goss CH, Quittner AL. Patient-reported outcomes in cystic fi brosis. Proc Am Thorac Soc. 2007 ; 4 (4): 378-386.
4. Modi AC, Quittner AL. Validation of a disease-specifi c measure of health-related quality of life for children with cystic fi brosis. J Pediatr Psychol. 2003 ; 28 (8): 535-545.
5. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Question naire in the United States: a health-related quality-of-life mea sure for cystic fi brosis. Chest. 2005; 128(4): 2347-2354.
6. Quittner AL, Sawicki GS, McMullen A, et al. Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. Qual Life Res. 2012 ; 21 (7): 1279-1290.
7. Arrington-Sanders R, Yi MS, Tsevat J, Wilmott RW, Mrus JM, Britto MT. Gender differences in health-related quality of life of adolescents with cystic fi brosis. Health Qual Life Outcomes. 2006 ; 4 : 5.
8. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fi brosis. Chest. 2002 ; 121 (1): 64-72.
9. Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Quality of life in cystic fi brosis: the impact of gender, general health perceptions and disease severity. J Cyst Fibros. 2003 ; 2 (4): 206-213.
10. Yi MS, Tsevat J, Wilmott RW, Kotagal UR, Britto MT. The impact of treatment of pulmonary exacerbations on the healthrelated quality of life of patients with cystic fi brosis: does hospitalization make a difference? J Pediatr. 2004 ; 144 (6): 711-718.
11. Abbott J, Hart A, Morton AM, Dey P, Conway SP, Webb AK. Can health-related quality of life predict survival in adults with cystic fi brosis? Am J Respir Crit Care Med. 2009 ; 179 (1): 54-58.
12. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fi brosis with hypertonic saline. N Engl J Med. 2006 ; 354 (3): 241-250.
13. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fi brosis. Am J Respir Crit Care Med. 2008 ; 178 (9): 921-928.
14. Ramsey BW, Davies J, McElvaney NG, et al ; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fi brosis and the G551D mutation. N Engl J Med. 2011; 365(18): 1663-1672.
15. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Effi cacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fi brosis. Chest. 2009 ; 135 (5): 1223-1232.
16. Goldbeck L, Zerrer S, Schmitz TG. Monitoring quality of life in outpatients with cystic fi brosis: feasibility and longitudinal results. J Cyst Fibros. 2007 ; 6 (3): 171-178.
17. Sawicki GS, Rasouliyan L, McMullen AH, et al. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fi brosis. Pediatr Pulmonol. 2011 ; 46 (1): 36-44.
18. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fi brosis. Am J Epidemiol. 2001 ; 153 (4): 345-352.
19. Singer JDW, Willett JB. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York, NY : Oxford University Press ; 2003.
20. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fi brosis and chronic Pseudomonas aeruginosa airway infection. Chest. 2009 ; 135 (6): 1610-1618.
21. Yankaskas JR, Marshall BC, Sufi an B, Simon RH, Rodman D. Cystic fi brosis adult care: consensus conference report. Chest. 2004 ; 125 (1)(suppl): 1S-39S.
22. Goldbeck L, Besier T, Hinz A, Singer S, Quittner AL ; TIDES Group. Prevalence of symptoms of anxiety and depression in German patients with cystic fi brosis. Chest. 2010 ; 138 (4): 929-936.
23. Sawicki GS, Sellers DE, Robinson WM. Self-reported physical and psychological symptom burden in adults with cystic fi brosis. J Pain Symptom Manage. 2008 ; 35 (4): 372-380.
24. Abbott J, Hart A, Morton A, Gee L, Conway S. Health-related quality of life in adults with cystic fi brosis: the role of coping. J Psychosom Res. 2008 ; 64 (2): 149-157.
25. Sawicki GS, Tiddens H. Managing treatment complexity in cystic fi brosis: challenges and opportunities. Pediatr Pulmonol. 2012 ; 47 (6): 523-533.
26. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fi brosis: challenges to disease self-management. J Cyst Fibros. 2009 ; 8 (2): 91-96.
27. Flume PA, O'Sullivan BP, Robinson KA, et al ; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fi brosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007 ; 176 (10): 957-969.